ECRM_1170x120_1-10-22

BioNTech

Pfizer reports COVID-19 vaccine 90% effective in Phase 3 trial

Pfizer reports COVID-19 vaccine 90% effective in Phase 3 trial

NEW YORK — Pfizer announced on Monday that the vaccine the company jointly developed with BioNTech was 90% effective in preventing COVID-19 infections in ongoing Phase 3 trials. Protection in patients was achieved seven days after the second of two doses, and 28 days after the first, according to preliminary findings. “The first set of

Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program

Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program

NEW YORK — Pfizer and BioNTech SE  announced Tuesday that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week.